We are focused
on treating cancer
Impilo is a privately held drug discovery and development company focused on a novel approach to enable nucleic acid-based medicines to effectively treat solid tumor cancers.
The Impilo Platform™ provides a tumor-targeted tissue penetration capability to specifically enhance nucleic acid drug delivery to tumors. Impilo is advancing internal programs and partnering efforts towards the clinic that hold potential to address unmet needs for solid tumor cancer patients.
Our experienced team
The company was founded by scientists and executives with deep experience and commitment to enable cancer patients to benefit from this important emerging drug class.
Scientific Advisory Board
Erkki Ruoslahti, MD, PhD
SAB Chairman
Kazuki Sugahara, MD, PhD
Physician and scientist at Columbia University College of Physicians and Surgeons
Our Partners
and Investors
Impilo will enter partnerships to access nucleic acid-based drug candidates to high-interest anticancer targets that may be enabled by the Impilo Platform™. The Company will also enter partnerships to apply the Impilo Platform™ to enable partners’ nucleic acid-based drugs a range of therapeutic modalities to effectively treat solid tumor cancers.